Journal
JOURNAL OF MOLECULAR DIAGNOSTICS
Volume 24, Issue 12, Pages 1279-1291Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jmoldx.2022.09.009
Keywords
-
Categories
Funding
- Illumina
- Asuragen
- Qiagen
- Perkin Elmer Inc.
- Bionano Genomics
- Agena
- Agendia
- PGDx
- Thermo Fisher Scientific
- Cepheid
- BMS
Ask authors/readers for more resources
This study demonstrates the utility of optical genome mapping (OGM) as a new technology for better characterization of hematological malignancies, including revealing the genetic complexity of tumors, with high technical performance and concordance. OGM has the potential to be a first-tier cytogenomic test for hematologic malignancies.
The current standard-of-care cytogenetic techniques for the analysis of hematological malignancies include karyotyping, fluorescence in situ hybridization, and chromosomal microarray, which are labor intensive and time and cost prohibitive, and they often do not reveal the genetic complexity of the tumor, demonstrating the need for alternative technology for better characterization of these tumors. Herein, we report the results from our clinical validation study and demonstrate the utility of optical genome mapping (OGM), evaluated using 92 sample runs (including replicates) that included 69 well -characterized unique samples (59 hematological neoplasms and 10 controls). The technical performance (quality control metrics) resulted in 100% first-pass rate, with analytical performance (concordance) showing a sensitivity of 98.7%, a specificity of 100%, and an accuracy of 99.2%. OGM demonstrated robust technical, analytical performance, and interrun, intrarun, and interinstrument reproducibility. The limit of detection was determined to be at 5% allele fraction for aneuploidy, translocation, interstitial deletion, and duplication. OGM identified several additional structural variations, revealing the genomic architecture in these neoplasms that provides an opportunity for better tumor classifi-cation, prognostication, risk stratification, and therapy selection. Overall, OGM has outperformed the standard-of-care tests in this study and demonstrated its potential as a first-tier cytogenomic test for hematologic malignancies. (J Mol Diagn 2022, 24: 1279-1291; https://doi.org/10.1016/ j.jmoldx.2022.09.009)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available